A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease

Clinical Trial ID: NCT02976129


The purpose of this study is to evaluate the efficacy and safety of V565 in participants with active Crohn's Disease.

This study will be a multiple-site, double-blind, placebo-controlled, parallel-group study in approximately 126 subjects with a confirmed diagnosis of CD for at least three months and have CD involving the ileum and/or colon. Following a screening period of up to 28 days, subjects will be randomly allocated into one of two treatment arms: either V565 or placebo using a 2:1 active:placebo ratio for a treatment period of 6 weeks. Subjects will be treated with study drug as an add-on to any permitted stable medications already being taken for CD.


Inclusion Criteria: - History of Crohn's Disease of at least 3 months duration prior to screening - CDAI score of ≥220 to ≤450 during screening - CRP ≥5 mg/L (or, if CRP is normal, FCP ≥250 µg/g) at screening - Permitted CD medication regimen expected to remain stable during the period of the study Exclusion Criteria: - Previous lack of response or current contra-indication to an anti-TNFα agent - Certain complications of Crohn's Disease that would make it hard to assess response to study drug - Known history or suspicion of IBD other than Crohn's disease - History of TB or latent TB infection that has not been treated - Any significant illness or condition which would preclude effective participation in the study - GI infection as demonstrated by presence of enteric pathogens - Pregnant or lactating women - Abdominal surgery in the previous 6 months - Unsuitable for inclusion in the study in the opinion of the investigator or sponsor for any reason that may compromise the subject's safety or confound data interpretation

  • Start Date


  • Last Updated


  • Sponsor

    VHsquared Ltd.

  • Condition Name

    Crohn's Disease

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.